生酮饮食治疗成人重症监护病房难治性癫痫持续状态的可行性、安全性与有效性
本研究为回顾性单中心研究,纳入2016年11月至2018年4月ICU内18至80岁难治性癫痫持续状态(RSE)成人患者,采用生酮饮食(KD)治疗方案。主要结局为尿酮体产生作为可行性生物标志物,次要结局包括RSE缓解及KD相关副作用。11例患者中90.9%(n=10)在中位1天内达到酮症,72.7%(n=8)RSE缓解,27.3%(n=3)进展为超难治性癫痫持续状态;副作用包括代谢性酸中毒、低血糖和低钠血症。作者结论认为KD可能可行、安全且有效,可能需要随机对照试验进一步检验其安全性和有效性。
要点
- 11例ICU成人RSE患者接受KD治疗,90.9%(n=10)在中位1天内达到酮症,提示KD在ICU中可能可行。
- 72.7%(n=8)患者RSE缓解,但27.3%(n=3)进展为超难治性癫痫持续状态。
- KD相关副作用包括代谢性酸中毒、低血糖和低钠血症。
- 启动KD前患者中位已使用三种抗癫痫药物,启动KD前RSE中位持续时间为1天;治疗延迟归因于丙泊酚给药。
- 作者结论认为KD可能可行、安全且有效,可能需要随机对照试验进一步检验其安全性和有效性。
适用人群与场景
- 年龄18至80岁、在ICU内诊断为难治性癫痫持续状态(RSE)并接受KD治疗方案的成人患者。
- 研究时间范围为2016年11月至2018年4月。
处置流程与药物剂量
- 采用KD治疗方案;启动KD前患者中位已使用三种抗癫痫药物,启动KD前RSE中位持续时间为1天。
- 治疗延迟归因于丙泊酚给药。
研究设计与关键结果
- 研究类型:回顾性、单中心研究;样本量11例成人RSE患者;平均年龄48岁,45%(n=5)为女性。
- 主要结局:90.9%(n=10)患者达到酮症,中位时间1天。
- 次要结局:RSE缓解72.7%(n=8);27.3%(n=3)进展为超难治性癫痫持续状态。
- 副作用包括代谢性酸中毒、低血糖和低钠血症;1例患者(20%)死亡。
证据类型、等级与局限
- 证据类型:回顾性、单中心研究。
- 作者结论:KD可能可行、安全且有效;可能需要随机对照试验进一步检验其安全性和有效性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为KD可能可行、安全且有效,可用于ICU内成人RSE的治疗。
- 作者认为可能需要随机对照试验进一步检验KD的安全性和有效性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Status, refractory status and super refractory status epilepticus are common neurologic emergencies. The objective of this study is to investigate the feasibility, safety and effectiveness of a ketogenic diet (KD) for refractory status epilepticus (RSE) in adults in the intensive care unit (ICU).
METHODS: We performed a retrospective, single-center study of patients between ages 18 and 80 years with RSE treated with a KD treatment algorithm from November 2016 through April 2018. The primary outcome measure was urine ketone body production as a biomarker of feasibility. Secondary measures included resolution of RSE and KD-related side effects.
RESULTS: There were 11 adults who were diagnosed with RSE that were treated with the KD. The mean age was 48 years, and 45% (n = 5) of the patients were women. The patients were prescribed a median of three anti-seizure medications before initiating the KD. The median duration of RSE before initiation of the KD was 1 day. Treatment delays were the result of Propofol administration. 90.9% (n = 10) of patients achieved ketosis within a median of 1 day. RSE resolved in 72.7% (n = 8) of patients; however, 27.3% (n = 3) developed super-refractory status epilepticus. Side effects included metabolic acidosis, hypoglycemia and hyponatremia. One patient (20%) died.
CONCLUSIONS: KD may be feasible, safe and effective for treatment of RSE in the ICU. A randomized controlled trial (RCT) may be indicated to further test the safety and efficacy of KD.
参考来源
- Francis BA, Fillenworth J, Gorelick P, et al. The Feasibility, Safety and Effectiveness of a Ketogenic Diet for Refractory Status Epilepticus in Adults in the Intensive Care Unit. Neurocrit Care. 2019. PMID: 30484010. doi:10.1007/s12028-018-0653-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。